Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Ipilimumab N01 + Cetuximab + Dabrafenib in MSS, BRAF V600E mCRC
NCT07506109Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, ipilimumab in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Mar 2026; status: recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07506109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506109.